Melanie Ramos
Family · Houston, TXNPI 1043891047
Payments from drug & device makers
Across 113 payments — averaging $29.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$346
- Astellas Pharma US Inc$323
- AstraZeneca$295
- Lilly USA, LLC$222
- GSK$213
- Pharmaessentia USA Corporation$201
- plus $2K from 17 others
What the payments were for
- Food & beverage$3,00291%
- Education$3119%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 11 | $346 |
| Astellas Pharma US Inc | 7 | $323 |
| AstraZeneca | 10 | $295 |
| Lilly USA, LLC | 8 | $222 |
| GSK | 8 | $213 |
| Pharmaessentia USA Corporation | 7 | $201 |
| AbbVie | 7 | $195 |
| Sobi, Inc | 7 | $192 |
| Bristol Myers Squibb | 7 | $177 |
| Novartis | 6 | $170 |
| Syndax Pharmaceuticals, Inc. | 5 | $163 |
| Daiichi Sankyo Inc. | 5 | $142 |
| Taiho Oncology, Inc. | 3 | $87 |
| Blueprint Medicines Corporation | 3 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $85 |
| Pfizer | 3 | $82 |
| Johnson & Johnson | 3 | $71 |
| Beigene USA, Inc. | 2 | $59 |
| Rigel Pharmaceuticals, Inc. | 2 | $58 |
| Merck | 2 | $54 |
| CTI Biopharma Corp. | 2 | $51 |
| Amgen | 1 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$3,313 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IclusigPonatinib Hcl | 36 | $650,160 |
| JakafiRuxolitinib Phosphate | 43 | $549,654 |
| ImbruvicaIbrutinib | 32 | $415,745 |
| BosulifBosutinib | 29 | $414,980 |
| SprycelDasatinib | 48 | $273,662 |
| VenclextaVenetoclax | 46 | $244,033 |
| BrukinsaZanubrutinib | 12 | $169,400 |
| CresembaIsavuconazonium Sulfate | 15 | $88,161 |
| Imatinib Mesylate | 12 | $31,903 |
| Voriconazole | 15 | $5,967 |
| ValacyclovirValacyclovir Hcl | 114 | $3,344 |
| Hydroxyurea | 29 | $492 |
| Ondansetron OdtOndansetron | 19 | $444 |
| Levofloxacin | 30 | $421 |
| Allopurinol | 33 | $190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $85 | $650,16036 claims |
| Incyte CorporationJakafi | $346 | $549,65443 claims |
| PfizerBosulif | $82 | $414,98029 claims |
| AbbVieVenclexta | $195 | $244,03346 claims |
| Beigene USA, Inc.Brukinsa | $59 | $169,40012 claims |
| Astellas Pharma US IncCresemba | $323 | $88,16115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in Houston
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- David WeirDallas$959K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.